THENNT.COM: Keyword Density Checker

Total words: 1617 | 2-word phrases: 422 | 3-word phrases: 461 | 4-word phrases: 480

PAGE INFO

Title	Try to keep the title under 60 characters (23 characters) Homepage – TheNNT
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (10 characters) Search by:

#	Keyword	Frequency	Density
1	nnt rating system	3	0.65%
2	direct oral anticoagulants	3	0.65%
3	to standard of	2	0.43%
4	intravenous magnesium as	2	0.43%
5	system to evaluate	2	0.43%
6	thennt editorial process	2	0.43%
7	standard of care	2	0.43%
8	diagnosis lr reviews	2	0.43%
9	to conventional anticoagulation	2	0.43%
10	type 2 diabetes	2	0.43%
11	therapy nnt reviews	2	0.43%
12	benefits and harms	2	0.43%
13	thennt rating system	2	0.43%
14	hypothermia following cardiac	2	0.43%
15	following cardiac arrest	2	0.43%
16	inhibitors and glp1	2	0.43%
17	sglt2 inhibitors and	2	0.43%
18	as an adjunct	2	0.43%
19	adjunct to standard	2	0.43%
20	an adjunct to	2	0.43%
21	conventional anticoagulants for	2	0.43%
22	vs conventional anticoagulants	2	0.43%
23	aggressive intravenous fluid	2	0.43%
24	anticoagulants vs conventional	2	0.43%
25	oral anticoagulants vs	2	0.43%
26	outcome read more	2	0.43%
27	magnesium as an	2	0.43%
28	increases adverse events	1	0.22%
29	diabetes but also	1	0.22%
30	but also increases	1	0.22%

#	Keyword	Frequency	Density
1	hypothermia following cardiac arrest	2	0.42%
2	an adjunct to standard	2	0.42%
3	sglt2 inhibitors and glp1	2	0.42%
4	vs conventional anticoagulants for	2	0.42%
5	anticoagulants vs conventional anticoagulants	2	0.42%
6	oral anticoagulants vs conventional	2	0.42%
7	direct oral anticoagulants vs	2	0.42%
8	to standard of care	2	0.42%
9	adjunct to standard of	2	0.42%
10	as an adjunct to	2	0.42%
11	intravenous magnesium as an	2	0.42%
12	magnesium as an adjunct	2	0.42%
13	for type 2 diabetes	1	0.21%
14	glp1 agonists to standard	1	0.21%
15	agonists for type 2	1	0.21%
16	of atrial fibrillation with	1	0.21%
17	adding sglt2 inhibitors and	1	0.21%
18	receptor agonists for type	1	0.21%
19	glp1 receptor agonists for	1	0.21%
20	inhibitors and glp1 agonists	1	0.21%
21	and glp1 agonists to	1	0.21%
22	reduces death nonfatal heart	1	0.21%
23	agonists to standard treatment	1	0.21%
24	of care for treatment	1	0.21%
25	standard of care for	1	0.21%
26	death nonfatal heart attack	1	0.21%
27	nonfatal heart attack and	1	0.21%
28	heart attack and severe	1	0.21%
29	attack and severe kidney	1	0.21%
30	and severe kidney disease	1	0.21%
31	severe kidney disease in	1	0.21%
32	type 2 diabetes but	1	0.21%
33	2 diabetes but also	1	0.21%
34	diabetes but also increases	1	0.21%
35	but also increases adverse	1	0.21%
36	also increases adverse events	1	0.21%
37	and glp1 receptor agonists	1	0.21%
38	2022 all rights reserved	1	0.21%
39	inhibitors and glp1 receptor	1	0.21%
40	nonhospitalized patients with covid19	1	0.21%

#	URL	Whois	Check